Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications

Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and... Diabetes is a serious metabolic disease in which chronic hyperglycemia results in diabetic microvascular and macrovascular complications from progressive vascular damage and dysfunction. Diabetes is life-threating and disabling, and is associated with costly complications and reduced life expectancy. Therefore, developing therapies for the treatment of diabetes is urgent and a significant challenge. Several peptides, including insulin, glucagon-like peptide-1, proinsulin C-peptide, and apelin, effectively normalize hyperglycemia and prevent hyperglycemia-induced diabetic complications, which are essential for the treatment of diabetes. However, a key limitation of peptide drugs for the clinical use is their short half-life. In this review, we describe the pathophysiological mechanisms and treatments of diabetic vascular complications. In addition, we discuss modification of peptide drugs by various approaches involving polymers to extend their blood circulating times and the use of the modified peptides in experimental and clinical studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioChip Journal Springer Journals

Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications

BioChip Journal , Volume 16 (2) – Jun 1, 2022

Loading next page...
 
/lp/springer-journals/polymer-based-delivery-of-peptide-drugs-to-treat-diabetes-normalizing-i0LNITUhJV
Publisher
Springer Journals
Copyright
Copyright © The Korean BioChip Society 2022
ISSN
1976-0280
eISSN
2092-7843
DOI
10.1007/s13206-022-00057-0
Publisher site
See Article on Publisher Site

Abstract

Diabetes is a serious metabolic disease in which chronic hyperglycemia results in diabetic microvascular and macrovascular complications from progressive vascular damage and dysfunction. Diabetes is life-threating and disabling, and is associated with costly complications and reduced life expectancy. Therefore, developing therapies for the treatment of diabetes is urgent and a significant challenge. Several peptides, including insulin, glucagon-like peptide-1, proinsulin C-peptide, and apelin, effectively normalize hyperglycemia and prevent hyperglycemia-induced diabetic complications, which are essential for the treatment of diabetes. However, a key limitation of peptide drugs for the clinical use is their short half-life. In this review, we describe the pathophysiological mechanisms and treatments of diabetic vascular complications. In addition, we discuss modification of peptide drugs by various approaches involving polymers to extend their blood circulating times and the use of the modified peptides in experimental and clinical studies.

Journal

BioChip JournalSpringer Journals

Published: Jun 1, 2022

Keywords: Diabetes; Hyperglycemia; Diabetic complications; Peptides; Polymers

References